Applied Therapeutics, Inc.
APLT
$0.441
-$0.0191-4.15%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -101.98% | -103.12% | -104.47% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -101.98% | -103.12% | -104.47% | -- | -- |
| Cost of Revenue | -3.48% | 4.14% | 24.06% | 66.28% | -- |
| Gross Profit | -9.08% | -19.85% | -46.56% | -48.32% | -- |
| SG&A Expenses | 76.80% | 22.50% | -2.90% | -24.50% | -29.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.85% | 0.88% | -8.69% | -10.15% | -19.68% |
| Operating Income | -47.65% | -17.59% | -5.75% | 22.20% | 31.39% |
| Income Before Tax | -94.08% | -119.93% | -178.41% | -45.15% | -1.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.08% | -119.93% | -178.41% | -45.15% | -1.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.08% | -119.93% | -178.41% | -45.15% | -1.34% |
| EBIT | -47.65% | -17.59% | -5.75% | 22.20% | 31.39% |
| EBITDA | -47.66% | -17.59% | -5.75% | -7.83% | -52.90% |
| EPS Basic | -11.87% | -17.49% | -1.33% | 46.15% | 60.13% |
| Normalized Basic EPS | -11.77% | -17.42% | -1.49% | 46.02% | 59.90% |
| EPS Diluted | -23.34% | -29.61% | -1.33% | 46.15% | 60.13% |
| Normalized Diluted EPS | -11.85% | -17.51% | -1.49% | 46.02% | 59.90% |
| Average Basic Shares Outstanding | 89.89% | 101.61% | 123.81% | 122.82% | 117.18% |
| Average Diluted Shares Outstanding | 92.96% | 105.24% | 123.81% | 122.82% | 117.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
